Peripheral blood lymphocytes (PBLs) are primary targets for gene therapy of inherited and acquired disorders of the immune system. We describe the development of an optimized transduction system that provides for highefficiency retrovirus-mediated gene transfer into primary PBLs. This optimized transduction protocol combines centrifugation of the lymphocytes (1000 x g) at the inception of transduction with phosphate depletion, low-temperature incubation (32°C), and the use of the packaging cell line PG13. Gene marking studies ofhuman and primate PBLs using these optimized transduction conditions demonstrated that the transduction efficiency exceeded 50% of the total lymphocyte population. The optimized transduction efficiency of PBLs with amphotropic retroviral vectors was in excess of 25%. The transduction procedure does not alter phenotype, viability, or expansion of the transduced cells. Our data indicate that this optimized transduction system leads to high-efficiency gene transfer into primary human lymphocytes, which obviates the requirement for selection of transduced cells prior to genetherapy procedures. Thus, large quantities of healthy retrovirally transduced lymphocytes containing a broad immunological repertoire can be generated for use in clinical protocols. Our results represent a significant improvement in the methodology for the transduction of lymphocytes for gene therapy.
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Peripheral blood lymphocytes (PBLs) have become a primary target for gene therapy of disorders of the immune system. Lymphocytes have successfully been utilized for gene transfer and expression of therapeutic genes in tissue culture, in vivo for preclinical studies in animal models, and in clinical protocols for disorders of the immune system, including adenosine deaminase (ADA) deficiency and AIDS (1) (2) (3) . Retroviral vectors are currently the most effective approach for the introduction of genes into PBLs. All retroviral vectors presently in use in clinical gene therapy trials are based on a Moloney murine leukemia virus backbone. Retroviral vectors are packaged into infectious particles after introduction into a retroviral packaging cell line. The species and cell type specificity (host range) of the retroviral vector particle is mainly determined by the type of envelope (env) gene contained within the packaging cell line. Murine amphotropic virusbased retroviral vector particles are capable of infecting human cells, but the transduction of human PBLs with amphotropic retroviral vectors generally results in low levels of gene transfer (1, (4) (5) (6) (7) (8) .
In an attempt to improve the efficiency of retroviralmediated gene transfer into human lymphocytes, we investigated the use of retroviral supernatants generated in a packaging cell line derived from the gibbon ape leukemia virus (GALV) envelope (PG13) (9) . The PG13 packaging cells express a hybrid retroviral genome in which the Moloney murine leukemia virus gag and pol genes are expressed on one expression vector, while the GALV env gene is expressed from another expression vector. The GALV envelope-containing retroviruses generated in this packaging cell line are capable of transducing a wide range of cell types, including human cells.
This report describes the development of a procedure that permits high-efficiency gene transfer into human and nonhuman primate PBLs. This transduction protocol combines the use of PG13-derived retroviral supernatants with metabolic induction of the GALV receptor, low-temperature incubation, and centrifugation. The high levels of gene transfer obtained with this methodology will greatly improve the prospect of using PBLs to successfully treat inherited and acquired immune deficiencies.
MATERIALS AND METHODS
Cell Culture and Retroviral Vectors. The cell lines used include PG13 (ATCC CRL-10686), PG13-LN (ATCC CRL-10685), and PA317 (10) . The PA317 and PG13 cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with L-glutamine at 0.30 mg/ml and 10% (vol/ vol) heat-inactivated fetal bovine serum. Cells were cultured at 37°C in a 5% C02/95% air humidified incubator. In the majority of these studies, two similar retroviral vectors were utilized for transduction/marking experiments, LN (11) and G3Na. Both vectors are simple long terminal repeat-driven neomycin phosphotransferase II gene-containing vectors that differ by the presence of multiple cloning sites in G3Na. The LN vector was produced in the PG13 GALV packaging cell line and had a titer of 6 x 105 G418-resistant colony-forming units per ml measured on HeLa cells. The G3Na vector was produced by the PA317 packaging cell line and had a titer of 8 x 105 G418-resistant colony-forming units per ml measured on HeLa cells. Additional retroviral vectors used include LXSN (11) and LASN (12) .
Isolation and Culture of Lymphocytes. A population of CD4-enriched lymphocytes was generated from CD8 magnetic bead-depleted (Dynal, Great Neck, NY) peripheral blood mononuclear cells. The human CD4-enriched cell population was resuspended in AIM-V modification 302 medium (Life Technologies, Grand Island, NY) containing 5% fetal bovine serum, OKT-3 (Ortho Diagnostics) at 10 ng/ml, and recombinant human interleukin 2 (rIL-2) at 200 units/ml and plated at 1 x 106 cells per ml in 6-well plates at 2 ml per well (Costar).
Abbreviations: PBL, peripheral blood lymphocyte; GALV, gibbon ape leukemia virus; ADA, adenosine deaminase; moi, multiplicity of infection; rIL-2, recombinant human interleukin 2; NeoR, neomycin resistance.
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The ADA patient whole blood lymphocytes were cultured in AIM-V medium supplemented with 5% fetal bovine serum and rIL-2 at 100 units/ml at a concentration of 2.5 X 105/ml in 24-well plates. Rhesus units/ml and phytohemagglutinin at 1 ,ug/ml for the rhesus cells. The phosphate-starved cells were subsequently exposed to the retroviral vector by the addition of supplemented supernatant, followed by centrifugation at 32°C for 60 min and incubation for 12 hr at 32°C in a 5% CO2 incubator. At the end of the transduction, the lymphocytes were pelleted, washed, and cultured at 1 x 106 cells per ml in AIM-V modification 302 supplemented with 5% fetal bovine serum and rIL-2 at 200 units/ml. For multiple transductions, the process was repeated immediately after the conclusion of the initial transduction. Lymphocyte viability and number were determined using trypan blue exclusion. The ADA patient whole blood lymphocytes were transduced with either PA317/LASN (moi = 2) or PG13/LXSN (moi = 4) retroviral vector supernatants 72 hr after plating. The transduction was performed using the intermediate protocol as above.
Analysis of Transduction Efficiency. The transduction efficiency of the retroviral vector preparations was analyzed using Southern blots of genomic DNA and semiquantitative PCR. Genomic DNA was isolated from populations of transduced lymphocytes by extraction using a TurboGen DNA isolation kit (Invitrogen). Ten micrograms of DNA was digested with the Sst I restriction enzyme, followed by Southern blot analysis using a neomycin-resistance (NeoR)-specific radiolabeled DNA probe. PCR for the NeoR or 13-actin gene was performed as described (13, 14) , using the NeoR primers (5'-GATA-GAAGGCGATGCGCFGCGAATCG-3', 5'-TCCATCATGG-CTGATGCAATGCGGC-3') or the f3-actin primers (5'-CATTGTGATGGACTCCGGAGACGG-3', 5'-CATCTC-CTGCTCGAAGTCTAGAGC-3'). The transduction efficiency of the ADA patient cells was analyzed by semiquantitative PCR for the NeoR gene using primers (5'-GGTGGAGAG-GCTATTCGGCTATGA-3', 5' -ATCCTGATCGACAA-GACCGGCTTC-3') in standard 100-j,l reaction mixtures with the addition of 0.01 ,Ci (1 Ci = 37 GBq) of [32P]dCTP. All quantitation was performed using a PhosphorImager (Molecular Dynamics).
RESULTS
Transduction Efficiency of Lymphocytes. Retroviralmediated gene transfer into primary lymphocytes of human and nonhuman primate origin resulted in low levels (<10%) of gene transfer (1, (4) (5) (6) (7) (8) . Transduced cells can be enriched for by culture in medium containing G418 to select for the NeoR gene but at the expense of decreased overall viability (6) . In this study, we sought to improve transduction conditions to optimize lymphocyte gene transfer efficiency.
Gene marking studies were initiated on rhesus and human CD4+ lymphocytes using a NeoR gene-containing retroviral vector produced in the GALV packaging cell line (PG13-LN) or a similar vector produced in an amphotropic packaging cell line (PA317-G3Na). Successful retroviral vector-mediated transduction of primary T lymphocytes requires the stimulation (e.g., using an antibody to CD3 plus rIL-2) of these quiescent cells to begin cell division. For human lymphocytes, we previously determined that 72 hr of stimulation yielded the highest amount of transduced cells (B.A.B. and R.A.M., unpublished observations). To determine this time for rhesus lymphocytes, a series of standard transduction experiments were initiated. Using standard transduction conditions (see Materials and Methods), the transduction efficiency for the rhesus lymphocytes was determined at 24 hr and 72 hr after stimulation. Semiquantitative PCR analysis of PA317-transduced rhesus lymphocytes showed a low level of transduction at 24 hr after stimulation but not at 72 hr after plating (Fig. 1A, lanes 1 and 6) , but no significant gene transfer was detected at either time point using the PG13 packaged vector (Fig. LA, lanes 7 and 13) . As suggested by previous experience (15), we next attempted to improve the standard gene transfer protocol by decreasing the temperature of incubation after addition of the retroviral vector supernatant. Rhesus lymphocytes were again subjected to a 32°C standard supernatant transduction at both 24 hr and 72 hr after plating using the PA317 and PG13 packaged retroviral vectors. The PCR data (Fig. 1A, lanes 2 ) was added to the 32°C incubation protocol. Centrifugation combined with low-temperature incubation increased the transduction efficiency of rhesus lymphocytes using the PG13-LN retroviral vector supernatant from 5% to 8% (Fig.  LA, lanes 8 and 9, respectively, normalized values) . Centrifugation did not increase the transduction efficiency of the amphotropic retroviral vector on rhesus lymphocytes (Fig. 1A,  lanes 2 and 3) . Addition of the centrifugation step increased the transduction efficiency of human lymphocytes with both types of retrovirus vectors when compared to the standard transduction conditions (Fig. 1C, compare lanes 1 to 2, 5 5, 9 , and 13), 32°C incubation and centrifugation at 1000 x g (lanes 2, 6, 10, and 15), Pi depletion followed by 32°C incubation (lanes 3, 7, 11, 14), P1 depletion followed by 32°C incubation with centrifugation at 1000 x g (lanes 4, The transduction efficiency of rhesus lymphocytes that underwent phosphate depletion and 32°C incubation during transduction with the PG13 retroviral vector supernatant was 10% (Fig. LA, lane 10) . To produce optimized transduction conditions, lymphocytes were subjected to transduction using phosphate depletion followed by exposure to supplemented retroviral supernatant, centrifugation at 1000 x g, and incubation at 32°C. These optimized conditions demonstrated a marked increase in the presence of the NeoR gene in rhesus lymphocytes exposed to both amphotropic and PG13 retroviral supernatants (Fig. 1A, lanes 4 and 11) . Under these transduction conditions, the PG13 supernatant transduced >70% of the rhesus lymphocytes, whereas the amphotropic supernatant transduced >40% of the rhesus lymphocytes.
The Fig. 1 B and D) .
The transduction efficiency of lymphocyte populations was also determined by Southern analysis. In this experiment, DNA from the samples analyzed in Fig. iC (donor no. 1 ) was subjected to Southern blot analysis; the resultant autoradiograph is shown in Fig. 2 . For the amphotropic retrovirustransduced samples, gene transfer efficiencies were <1% with only the optimized samples visualized in this assay (Fig. 2 Clinical Implications of the Optimized Transduction Procedure. To demonstrate that lymphocytes transduced with PG13-packaged retroviral vectors using optimal conditions retain their ability to function in the context of a gene therapy setting, we analyzed the transduction efficiency of the PA317 and PG13 retroviral vector supernatants on lymphocytes from a patient enrolled in the ADA deficiency gene therapy clinical trial.
To perform this study, whole blood lymphocytes were transduced with the PA317/LASN and PG13/LXSN retroviral vector supernatants using the intermediate transduction (Fig. 3) .
DISCUSSION
The use of lymphocytes for gene therapy for inherited and acquired disorders of the immune system has been in development for several years (1) (2) (3) (4) (5) (6) (7) (8) . One problem in the use of lymphocytes for gene therapy has been the low level of gene transfer. In this report, we investigated several approaches to increase the levels of gene transfer into PBLs and describe a transduction system that results in high-efficiency retroviralmediated gene transfer into primary lymphocytes. The results obtained were for both CD4-enriched T lymphocytes (Figs. 1 and 2, Table 1 ) as well as total T lymphocytes (Fig. 3) .
High-efficiency gene transfer into human and rhesus PBLs was achieved by combining the use of PG13-derived retroviral supernatant with low-temperature incubation, centrifugation, and induction of the GALV receptor by phosphate depletion. By using this combined procedure, transduction efficiencies ranging from 45% to 80% were routinely observed in human and rhesus PBLs using PG13-packaged vectors and 20-40% with the PA317-packaged vectors. This is a significant improvement compared to the low levels of gene transfer (1-10%) in PBLs that have previously been reported (4) (5) (6) (7) (8) . Transduction of lymphocytes with PG13-based supernatants under the optimized protocol generates a population of transduced cells that does not require selection to enrich for transduced cells. For lymphocyte-based gene therapy trials, these techniques permit reinfusion of large quantities of healthy lymphocytes that have a representative immunological repertoire.
The efficiency of gene transfer by both amphotropic and GALV envelope-containing supernatants was significantly affected by the individual components of the transduction system. Decreasing the temperature of incubation from 37°C to 32°C during the standard transduction protocol increased the transduction efficiency 2-to 4-fold. The increased levels of gene transfer observed at 32°C are most likely due to an increase in the half-life of the retrovirus at the lower temperature. The incorporation of a centrifugation step (1000 x g) along with decreased transduction temperature served to further increase (2-to 3-fold) the gene transfer efficiency in the intermediate transduction protocol. The mechanism by which centrifugation increases the transduction efficiency is unclear, but other investigators have observed similar results in other cell types (15) . Infrequently, the centrifugation step used in the intermediate transduction protocol was associated with loss or inactivation of the vector supernatant, resulting in minimal transduction (see Fig. IA, lane 3 and Fig. 1C, lane 15) . The cause of these failures is unknown, but we have not observed Proc. Natl. Acad. Sci. USA 92 (1995) Nen(+l a similar loss in the optimized protocol, which also uses centrifugation.
Phosphate depletion of the lymphocytes was used in an attempt to increase the gene expression of the amphotropic and GALV receptors/phosphate symporters prior to transduction. Phosphate depletion dramatically increased the transduction efficiency. Lymphocytes that were starved and then transduced at the low temperature with the PG13-LN supernatant had levels of gene transfer >25% as opposed to the 2% observed without the phosphate deprivation. Miller and coworkers (17) previously observed that starvation of rat fibroblasts in phosphate-free medium increases the RNA levels for both the GALV and amphotropic receptors. It is unclear whether the increased gene expression leads to greater expression of the retroviral receptor proteins on the surface of the cell, but our transduction data strongly suggest that receptor protein levels must increase. Taken together, the combination of different transduction techniques was developed into an optimal transduction protocol that results in >50% lymphocyte transduction using PG13-packaged vectors and >25% transduction efficiencies with PA317-packaged retroviral vectors.
As a test of a potential clinical application, we demonstrated the improved effectiveness of the PG13 retroviral vector supernatant for transduction of ADA patient lymphocytes that had previously been demonstrated to transduce poorly with amphotropic retroviral vector supernatants. In our studies, the use of a PG13 retroviral vector supernatant transduced 42% of this patient's lymphocytes in comparison to an amphotropic retroviral vector that only transduced 3% of a total lymphocyte population. The different moi values used for this transduction study were not likely the cause of this increased rate, as varying the moi from 1 up to 10 with amphotropic retroviral vectors had previously not produced a difference in transduction efficiency with this patient (gene transfer efficiency was always s1%; data not shown).
In conclusion, we have developed a high-efficiency gene transduction system for human PBLs. The protocol is straightforward and easy to apply. The technique does not require the development of special vectors or packaging cell lines and may be used effectively with preexisting amphotropic retroviral vectors. The transduction approach discussed here could lead to a significant increase in the effectiveness of clinical trials for gene therapy of disorders of the immune system. It is also possible that this system could be widely applied to other target cells for gene therapy and may have applications for use in the development of gene therapies for a number of diseases.
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